Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases by leveraging several core strengths:

• Existing revenue generation advances their growth: Their existing revenue generation from their research and development, supply contracts, and commercial partnerships can be used to invest in the advancement of their clinical pipeline.
• Icon-Technology Modular and proprietary vaccine technology : Their vaccine platform takes a modular approach to live virus vaccine development and is based on the use of different types of poxviruses, notably their MVA-BN viral vector with a favorable safety profile. These viruses can be used in various combinations for both the prime and booster applications in both cancer and infectious diseases.
• Icon-Manufacturing Commercial-scale cGMP production facility: Their ability to effectively and efficiently produce their live virus vaccines has been demonstrated by our production of more than 28 million doses of MVA-BN smallpox vaccine and more than 2 million doses of our MVA-BN Filo product candidate for Ebola to date, as well as production of all clinical materials.
• Icon-Relationships Ongoing relationships with government agencies: They have entered into research and development contracts with the U.S. Government worth more than USD 1.2 billion in revenue. Contract partners include HHS, NIH, BARDA, NCI, DOD, and the DHS, spanning multiple disease areas and biological threats.
• Icon-Collaborations Industry partnerships and collaborations: They have entered a broad partnership with Janssen, under which they have outlicensed their MVA-BN vaccine technology for Ebola, HPV, HIV and Hepatitis B vaccines. In addition, they are collaborating with Bristol-Myers Squibb, Roche and AstraZeneca to explore their cancer immunotherapy candidates in combination with immune checkpoint inhibitors from their companies.